{"issuance_frequency":"","notes_translated":{"fr":"Les changements survenus après l’avis de conformité (AC) se définissent comme toute modification d’une drogue nouvelle pour laquelle un AC a été délivré aux termes de l’article C.08.004 du Règlement sur les aliments et drogues. Bon nombre de ces changements peuvent contribuer à améliorer la qualité du médicament ou l’efficacité du processus de fabrication, ou ne servent qu’à des fins de commercialisation. Les modifications apportées à l’étiquette d’un médicament peuvent constituer de nouvelles indications, une amélioration de la gestion des risques associés à un produit par l’ajout de mises en garde, une restriction relative au public visé ou une modification du régime de dosage, etc.","en":"A post-NOC change is any change that is made to a new drug that has received a NOC pursuant to section C.08.004 of the Food and Drug Regulations. Many of these changes may be made to improve the quality of the drug product or the efficiency of the manufacturing process, or they could be made for marketing considerations. Changes to the labelling of a drug product could include adding new indications, improving the management of risk for a product by adding warnings, limiting the target population or changing the dosage regime etc."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"ab2da751-e988-4280-940e-eeef74e8e4d8","metadata_created":"2021-07-07T19:51:35.717404","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-07T19:51:35.717410","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-07","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["Post-avis de conformité","changements d'AC","document-cadre","médicaments pharmaceutiques","biologiques","radiopharmaceutiques","médicaments à usage humain uniquement"],"en":["Post-Notice of Compliance","NOC Changes","framework document","pharmaceutical","biologic","radiopharmaceutical drugs","drugs for human use only"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Ligne directrice : Changements survenus après l'avis de conformité (AC) : Document cadre (Médicaments pharmaceutiques, biologiques et radiopharmaceutiques à usage humain seulement)","en":"Guidance document: Post-Notice of Compliance (NOC) Changes: Framework Document (Pharmaceutical, biologic and radiopharmaceutical drugs for human use only)"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"ab2da751-e988-4280-940e-eeef74e8e4d8","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"fb06f5e2-d764-42b0-922b-9324036db67e","related_relationship":"","name_translated":{"fr":"Ligne directrice : Changements survenus après l'avis de conformité (AC) : Document cadre (Médicaments pharmaceutiques, biologiques et radiopharmaceutiques à usage humain seulement)","en":"Guidance document: Post-Notice of Compliance (NOC) Changes: Framework Document (Pharmaceutical, biologic and radiopharmaceutical drugs for human use only)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance document: Post-Notice of Compliance (NOC) Changes: Framework Document (Pharmaceutical, biologic and radiopharmaceutical drugs for human use only)","language":["en"],"created":"2021-07-07T19:51:35.849203","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/post-notice-compliance-changes/framework-2019/document.html#a1","last_modified":null,"position":0,"revision_id":"ae05b9e7-1d93-41c7-9f18-01c59ff901f9","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"ab2da751-e988-4280-940e-eeef74e8e4d8","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"42ddddef-118e-41d8-a9f6-a44803ee8640","related_relationship":"","name_translated":{"fr":"Ligne directrice : Changements survenus après l'avis de conformité (AC) : Document cadre (Médicaments pharmaceutiques, biologiques et radiopharmaceutiques à usage humain seulement)","en":"Guidance document: Post-Notice of Compliance (NOC) Changes: Framework Document (Pharmaceutical, biologic and radiopharmaceutical drugs for human use only)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance document: Post-Notice of Compliance (NOC) Changes: Framework Document (Pharmaceutical, biologic and radiopharmaceutical drugs for human use only)","language":["fr"],"created":"2021-07-07T19:51:35.849209","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/changements-survenus-apres-avis-conformite/cadre-2019/document.html#a1","last_modified":null,"position":1,"revision_id":"ae05b9e7-1d93-41c7-9f18-01c59ff901f9","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2020-04-01 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"ab2da751-e988-4280-940e-eeef74e8e4d8","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"A post-NOC change is any change that is made to a new drug that has received a NOC pursuant to section C.08.004 of the Food and Drug Regulations. Many of these changes may be made to improve the quality of the drug product or the efficiency of the manufacturing process, or they could be made for marketing considerations. Changes to the labelling of a drug product could include adding new indications, improving the management of risk for a product by adding warnings, limiting the target population or changing the dosage regime etc.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance document: Post-Notice of Compliance (NOC) Changes: Framework Document (Pharmaceutical, biologic and radiopharmaceutical drugs for human use only)","revision_id":"ae05b9e7-1d93-41c7-9f18-01c59ff901f9"}